Cysticercosis Treatment Market By Product 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Cysticercosis Treatment Market
Cysticercosis Treatment Market: By Product (Biopsy, Computed Tomography/Magnetic Resonance Imaging, and Enzyme Linked Immunoelectrotransfer Blot (EITB)/Western Blot), By Technology (Praziquantel, and Albendazole), & By Region-Forecast (2016-2021)
Report Code : HCR 0237
Updated Date: 08 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Cysticercosis Treatment Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Cysticercosis Treatment Market– Market Forces
   4.1. Drivers
      4.1.1. Increasing government initiative to eradicate Cysticercosis
      4.1.2. Rise in the in incidences of Cysticercosis in developing regions
      4.1.3. Increasing awareness among people for Cysticercosis
   4.2. Restraints
      4.2.1. Higher cost of research and development
      4.2.2. High frequency of adverse reactions
   4.3. Opportunities
      4.3.1. Emerging economies
      4.3.2. Increase in adoption of cysticercosis treatment
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Cysticercosis Treatment Market, By Diagnosis
   5.1. Biopsy
   5.2. Computed Tomography/Magnetic Resonance Imaging
   5.3. Enzyme Linked Immunoelectrotransfer Blot (EITB)/Western Blot
6. Cysticercosis Treatment Market, By Treatment
   6.1. Praziquantel (Isoquinolone),
   6.2. Albendazole (Imidazole)
7. Cysticercosis Treatment Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Cysticercosis Treatment – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
   9.1. GlaxoSmithKline
   9.2. Amedra Pharmaceuticals
   9.3. Bayer AG
   9.4. Klarsehen India
   9.5. Ranbaxy
   9.6. Salius
   9.7. Cipla
   9.8. Pharmaco-Kinesis Corporation
   9.9. Bonaide
   9.10. Taj Pharmaceuticals Limited
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix

   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Expert Insights
Cysticercosis or Taeniasis is an infection caused primarily due to tapeworms. The largest frequency of infections is caused by the Taenia solium variety of tapeworms which are found in pork. Infection occurs when the tapeworm larvae enter the body and form cysticerci. Infection is found most often in rural, developing countries with poor hygiene where pigs are allowed to roam freely and injest human faeces. Globally, increasing government initiative to eradicate Cysticercosis, rise in the in incidences of Cysticercosis in developing regions, and increasing awareness among people for Cysticercosis are the prime growth drivers of global cysticercosis treatment market. In addition, increase in adoption of cysticercosis treatment, and emerging economies such as China, India and others, will create new opportunities for global cysticercosis treatment market. However, higher cost of the research and development, and high frequency of adverse reactions, owing to the body’s inflammatory reaction to the dying parasites are the key restraints for global cysticercosis treatment market.

This report identifies the global cysticercosis treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global cysticercosis treatment market.
Cysticercosis Treatment Market

Geographically Latin America dominated global cysticercosis treatment market, and Asia Pacific is projected to have fastest growth, owing to rapidly increasing incidences of Cysticercosis, awareness among people and government regulations in developing nations such as China, and India in this region. Among all the treatments, albendazole (imidazole) has the highest market share in global cysticercosis treatment market.

This report segments global cysticercosis treatment market on the basis of diagnosis, treatment, and regional market as follows:

  • Cysticercosis Treatment Market, By Diagnosis: Biopsy, Computed Tomography/Magnetic Resonance Imaging, and Enzyme Linked Immunoelectrotransfer Blot (EITB)/Western Blot
  • The report has focused study on cysticercosis treatment market by basis of treatment such as: Praziquantel (Isoquinolone), and Albendazole (Imidazole)
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

Sample Companies Profiled in this Report are:
  • GlaxoSmithKline
  • Amedra Pharmaceuticals
  • Bayer AG
  • Klarsehen India
  • Ranbaxy
  • 10+
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports